Table 2.

Auto-immune conditions and risk of NHL

Study author, year, and location*Type of studyRisk estimate (OR/RR and 95% CI)
Rheumatoid arthritis
    Gridley (1993), Sweden (13)Cohort, Population based1.9 (1.3–2.6)
    Kauppi (1997), Finland (14)Cohort, Population based2.2 (1.5–3.1)
    Tavani (2000), Italy (11)CC, Population based1.7 (0.9–3.4)
    Ekstrom (2003), Sweden (15)Cohort, Population based1.9 (1.7–2.1)
    Becker (2005), Germany (7)CC, Population based0.7 (0.3–1.4)
    Engels (2005), United States (16)CC, Population based1.3 (0.8–2.1)
    Zintzaras (2005), multinational (17)Meta-analysis, cohorts3.9 (2.5–5.9)
    Smedby (2006), Denmark/Sweden (18)CC, Population based1.5 (1.1–1.9)
Systemic lupus erythematosis
    Gridley (1993), Sweden (13)Cohort, Population based1.9 (1.3–2.6)
    Vineis (2000), Italy (4)CC, Population based8.4 (1.6–45)
    Bjornadal (2002), Sweden (19)Cohort, Population based2.9 (2.0–4.0)
    Bernatsky (2005), multinational (20)Cohort, ?Population based3.6 (2.6–4.9)
    Engels (2005), United States (16)CC, Population based4.2 (1.2–15)
    Zintzaris (2005), multinational (17)Meta-analysis, cohorts7.4 (3.3–17)
    Smedby (2006), Denmark/Sweden (18)CC, Population based4.6 (1.0–22)
Sjogren's syndrome
    Kauppi (1993), Finland (14)Cohort, Population based8.7 (4.3–16)
    Fabbro-Peray (2000), France (5)CC, Population based5.1 (0.9–28)
    Engels (2005), United States (16)CC, Population based13 (1.7–100)
    Zintzaris (2005), multinational (17)Meta-analysis, cohorts19 (10–37)
    Smedby (2006), Denmark/Sweden (18)CC, Population based6.1 (1.4–27)
Psoriasis
    Hannuksela-Svahn (2000), Finland (21)Cohort, Population based2.2 (1.4–3.4)
    Tavani (2000), Italy (11)CC, Hospital based2.5 (0.8–7.3)
    Vineis (2000), Italy (4)CC, Population based1.2 (0.8–1.8)
    Gelfand (2003),United Kingdom (22)Cohort, GP based3.0 (1.8–4.8)
    Smedby (2006), Denmark/Sweden (18)CC, Population based1.2 (0.9–1.5)
  • * Numbers are references added to the supplementary data.

  • CC = Case-control study.

  • Based on data linkage between patients hospitalized with the disease and population-based cancer data.